All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to Meral Beksaç, Ankara University, Ankara, TR. We asked, Can lenalidomide maintenance be given to patients with MM and COVID-19 infection?
Can lenalidomide maintenance be given to patients with MM and COVID-19 infection?
Beksaç provides an overview of the outcomes for patients with concurrent multiple myeloma and COVID-19 infection who received lenalidomide compared with patients who did not receive lenalidomide. These outcomes included the rate of severe COVID-19 infection and fatality.
IMW 2019 | Results from the phase II PLEIADES trial (MMY2040): dara SC combination therapy
Results from the phase II PLEIADES trial which aimed to investigate the efficacy and safety of dara SC when combined with standard MM regimens
Predictive factors of mortality in patients with hematological malignancies diagnosed with COVID-19
During this COVID-19 pandemic, patients with hematological malignancies—who are immunocompromised because of the cancer itself, immunosuppressive...
Subscribe to get the best content related to multiple myeloma delivered to your inbox